Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

Pfizer

Status: Completed

Conditions: Pneumococcal Disease

Treatments: Biological: Prevenar 13

Study type: Observational

Funder types: Industry

Identifiers

NCT01396434

B1851076

Details and patient eligibility

About

Prevenar 13 is safe for administration to Filipinos.

Full description

Filipino patients prescribed and administered with the vaccine will be monitored for safety Patients prescribed with the vaccine who provides consent for inclusion to the study will be observed.

Enrollment: 3,006 patients

Sex: All

Ages: 6+ weeks old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients prescribed with the vaccine

Exclusion criteria

Patients with hypersensitivity to the vaccine

Trial design

3,006 participants in 1 patient group

Prevenar 13 patients

Treatment:

Biological: Prevenar 13